ResearcherNorth Dakota State UniversityNo recent work listed

Kaitlin M. Dailey

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8834-0293; OpenAlex author ID A5038664061. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2023: 1 paper

Papers 1

An intravenous pancreatic cancer therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic. Co-author DOI 10.1371/journal.pone.0289183 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Megan Orr · 1 shared paper, 2023 · strength 0.18
- Paper An intravenous pancreatic cancer therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic. DOI 10.1371/journal.pone.0289183 ↗
Amanda E. Brooks · 1 shared paper, 2023 · strength 0.18
- Paper An intravenous pancreatic cancer therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic. DOI 10.1371/journal.pone.0289183 ↗
Sanku Mallik · 1 shared paper, 2023 · strength 0.18
- Paper An intravenous pancreatic cancer therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic. DOI 10.1371/journal.pone.0289183 ↗
Michael Anthony Hollingsworth · 1 shared paper, 2023 · strength 0.18
- Paper An intravenous pancreatic cancer therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic. DOI 10.1371/journal.pone.0289183 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.